Yttrium-90-labelled somatostatin-analogue for cancer treatment

被引：289

作者：

Otte, A ^{[1
]}

Mueller-Brand, J

Dellas, S

Nitzsche, EU

Herrmann, R

Maecke, HR

机构：

[1] Univ Basel Hosp, Inst Nucl Med, Dept Med Radiol, CH-4031 Basel, Switzerland

[2] Univ Basel Hosp, Inst Nucl Med, Dept Oncol, CH-4031 Basel, Switzerland

[3] Univ Hosp, Dept Nucl Med, Freiburg, Germany

来源：

LANCET | 1998年 / 351卷 / 9100期

关键词：

D O I：

10.1016/S0140-6736(05)78355-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：417 / 418

页数：2

共 4 条

[1] Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA(0),D-Phe(1),Tyr(3)]octreotide, a promising somatostatin analogue for radionuclide therapy [J].

deJong, M ;

Bakker, WH ;

Krenning, EP ;

Breeman, WAP ;

vanderPluijm, ME ;

Bernard, BF ;

Visser, TJ ;

Jermann, E ;

Behe, M ;

Powell, P ;

Macke, HR .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1997, 24 (04) :368-371

[2] Somatostatin receptor: Scintigraphy and radionuclide therapy [J].

Krenning, EP ;

Kooij, PPM ;

Pauwels, S ;

Breeman, WAP ;

Postema, PTE ;

DeHerder, WW ;

Valkema, R ;

Kwekkeboom, DJ .

DIGESTION, 1996, 57 :57-61

[3] Drug therapy - Octreotide [J].

Lamberts, SWJ ;

vanderLely, AJ ;

deHerder, WW ;

Hofland, LJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (04) :246-254

[4]

Otte A, 1997, EUR J NUCL MED, V24, P792

← 1 →